Drug
Ingenol Mebutate
Ingenol Mebutate: highest development phase Approved, developed by LEO Pharma. 2 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| PICATO | Approved | |
| Ingenol mebutate NCT01449513 | Phase 1 | Actinic Keratosis |
Latest
- PICATO: patent 9833428 expires 2026-12-18
- PICATO: patent 8372828 expires 2026-12-18
- PICATO: patent 8372827 expires 2026-12-18
- PICATO: patent 8377919 expires 2026-12-18
- PICATO: patent 9833429 expires 2026-12-18
Follow Ingenol Mebutate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.